Ilaris
Novartis, Switzerland
$7400.00-
SelectSpecification/Number
-
ParameterDetailed information
-
NoticeCustoms clearance instructions
-
Required readingConsumption notice
- Description
- Information
INDICATIONS AND USAGE
Periodic Fever Syndromes
ILARIS® (canakinumab) is an interleukin-1β (IL-1β) blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes:
Cryopyrin-Associated Periodic Syndromes (CAPS)
ILARIS is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including:
Familial Cold Autoinflammatory Syndrome (FCAS)
Muckle-Wells Syndrome (MWS)
Tumor Necrosis Factor Receptor (TNF) Associated Periodic Syndrome (TRAPS)
ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients.
Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
ILARIS is indicated for the treatment of Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients.
Familial Mediterranean Fever (FMF)
ILARIS is indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients.
Still’s Disease (Adult-Onset Still’s Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [SJIA])
ILARIS is indicated for the treatment of active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.
DOSAGE
General Dosing Information
INJECTION FOR SUBCUTANEOUS USE ONLY.
Cryopyrin-Associated Periodic Syndromes (CAPS)
The recommended dose of ILARIS is 150 mg for CAPS patients with body weight greater than 40 kg. For CAPS patients with body weight greater than or equal to 15 kg and less than or equal to 40 kg, the recommended dose is 2 mg/kg. For children 15 to 40 kg with an inadequate response, the dose can be increased to 3 mg/kg.
ILARIS is administered every 8 weeks.
Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD), and Familial Mediterranean Fever (FMF)
The recommended dose of ILARIS for TRAPS, HIDS/MKD, and FMF patients is based on body weight.
For patients with body weight less than or equal to 40 kg, the recommended dose is 2 mg/kg administered every 4 weeks. The dose can be increased to 4 mg/kg every 4 weeks if the clinical response is not adequate.
For patients with body weight greater than 40 kg, the recommended dose is 150 mg administered every 4 weeks. The dose can be increased to 300 mg every 4 weeks if the clinical response is not adequate.
Still’s Disease, Including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA)
The recommended dose of ILARIS for patients with Still’s disease (AOSD and SJIA) with a body weight greater than or equal to 7.5 kg is 4 mg/kg (with a maximum of 300 mg) administered every 4 weeks.
ADVERSE REACTIONS
decreased ability of your body to fight infections (immunosuppression)
Allergic reactions
risk of infection with live vaccines
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/7d271f3b-e4f9-4d80-8dcf-28d49123f80e/spl-doc?hl=Ilaris
Ilarisinformation
No information yet!!!